Ring Therapeutics is a biotechnology company developing a novel class of genetic medicines based on anellovectors, which are engineered versions of naturally occurring viruses called anelloviruses. The company's platform technology aims to deliver therapeutic genes safely and effectively to treat various diseases, particularly focusing on applications where precise gene delivery is crucial.
The company was founded based on research into anelloviruses, which are abundant in humans but don't cause disease, making them potentially safer vectors for gene therapy compared to traditional viral vectors. Ring Therapeutics has attracted attention in the gene therapy space for its innovative approach to addressing some of the safety and efficacy challenges that have historically limited genetic medicine development.
Ring Therapeutics has received investment from 1 venture capital firm.
Biotechnology company developing genetic medicines using engineered anellovectors for safer gene therapy delivery.
Ring Therapeutics has received investment from Flagship Pioneering. These venture capital firms and investors provide both capital and strategic support.
Ring Therapeutics operates in the Biotech sector. Biotechnology company developing genetic medicines using engineered anellovectors for safer gene therapy delivery.
